Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China.
Department of Rheumatology, Beijing Key Lab for Immune-Mediated Inflammatory Diseases, China-Japan Friendship Hospital, Beijing 100029, China.
Mediators Inflamm. 2020 Oct 26;2020:7948095. doi: 10.1155/2020/7948095. eCollection 2020.
Soluble CD206 (sCD206) is considered a macrophage activation marker, and a previous study proved it as a potential biomarker to predict the severity of anti-melanoma differentiation-associated gene 5- (anti-MDA-5-) positive dermatomyositis- (DM-) associated interstitial lung disease (ILD). To investigate the role of sCD206 in various subtypes of DM, we evaluated the serum level of sCD206 in patients with different myositis-specific autoantibodies besides anti-MDA-5 and clarified its clinical significance.
Commercial enzyme-linked immunosorbent assay kits were used to detect serum concentrations of sCD206 in 150 patients with DM and 52 healthy controls (HCs). Correlations between sCD206 levels and clinical features, laboratory examinations, and pulmonary function test parameters were analysed.
The median concentrations of serum sCD206 in DM patients were significantly higher than those in HCs ( < 0.0001). Furthermore, median sCD206 levels were elevated in patients with ILD ( = 0.001), especially in those with rapidly progressive ILD (RP-ILD) ( < 0.0001). In addition, sCD206 levels were negatively correlated with the pulmonary function test results, including the percent predicted forced vital capacity ( = -0.234, = 0.023), percent predicted forced expiratory volume in one second ( = -0.225, = 0.030), and percent predicted carbon monoxide diffusion capacity ( = -0.261, = 0.014). Age- and gender-adjusted multivariable analysis showed that sCD206 was an independent prognostic factor for RP-ILD in patients with DM. A longitudinal study showed that sCD206 levels were positively correlated with the physician global assessment visual analog scale scores ( = 54.201, = 0.001).
Serum sCD206 levels were significantly increased in patients with DM and significantly associated with RP-ILD, suggesting that sCD206 is an important biological predictor of RP-ILD in patients with DM.
可溶性 CD206（sCD206）被认为是巨噬细胞活化标志物，先前的研究证明其是预测抗黑色素瘤分化相关基因 5 阳性（抗 MDA-5 阳性）皮肌炎相关间质性肺病（ILD）严重程度的潜在生物标志物。为了研究 sCD206 在不同皮肌炎亚型中的作用，我们评估了除抗 MDA-5 以外，具有不同肌炎特异性自身抗体的皮肌炎患者血清 sCD206 水平，并阐明了其临床意义。
采用商业酶联免疫吸附试验试剂盒检测 150 例皮肌炎患者和 52 例健康对照者（HCs）的血清 sCD206 浓度。分析 sCD206 水平与临床特征、实验室检查和肺功能检查参数之间的相关性。
皮肌炎患者血清 sCD206 中位数浓度明显高于 HCs（<0.0001）。此外，ILD 患者 sCD206 中位数浓度升高（=0.001），尤其是快速进展性ILD（RP-ILD）患者（<0.0001）。此外，sCD206 水平与肺功能检查结果呈负相关，包括用力肺活量预计值百分比（=-0.234，=0.023）、一秒用力呼气容积预计值百分比（=-0.225，=0.030）和一氧化碳弥散量预计值百分比（=-0.261，=0.014）。年龄和性别校正的多变量分析显示，sCD206 是皮肌炎患者发生 RP-ILD 的独立预后因素。一项纵向研究显示，sCD206 水平与医生整体评估视觉模拟量表评分呈正相关（=54.201，=0.001）。
皮肌炎患者血清 sCD206 水平显著升高，与 RP-ILD 显著相关，提示 sCD206 是皮肌炎患者 RP-ILD 的重要生物学预测因子。
